Clinical Trials Browser

Has results × Myelodysplastic Syndromes × Granulocyte-Macrophage Colony-Stimulating Factor × Clear all

Hodgkin Disease, Leukemia, Leukemia, Lymphoid, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell

NCT01700673 2022-10-18

Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS

Phase 2 Completed

25 enrolled 13 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT00488592 2021-07-12

Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers

Phase 2 Completed

10 enrolled 7 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

NCT01158118 2017-06-05

Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors

Phase 2 Completed

48 enrolled 17 charts

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00665002 2015-02-27

Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Myeloid Neoplasms

Phase NA Completed

16 enrolled 8 charts

MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Neoplasms, Leukemia, Myeloid, Acute

NCT01542684 2014-04-30

Study of Azacytidine Followed by GM-CSF in Patients With Myelodysplastic Syndrome (MDS)

Phase 2 Terminated

8 enrolled 5 charts

MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes

Clinical Trials

Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis

Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS

Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers

Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors

Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Myeloid Neoplasms

Study of Azacytidine Followed by GM-CSF in Patients With Myelodysplastic Syndrome (MDS)